Please assess the completion status of the following clinical trial:

Trial Title: Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented compensated chronic hepatitis B defined by clinical history compatible with compensated chronic hepatitis B~* Detectable serum HBsAg at the Screening visit~Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Patient is pregnant or breastfeeding.~* Patient is coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV~* Patient previously received lamivudine, adefovir dipivoxil, or an investigational anti-hepatitis B virus (HBV) nucleoside or nucleotide analog at any time~* Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).